MAIA Biotechnology (MAIA)
Developing ateganosine, a telomere-targeting treatment for later-line lung cancer.
Something off on this page? Send us feedback.
Develops ateganosine, a telomere-targeting cancer treatment being tested with checkpoint inhibitors for later-line non-small cell lung cancer. Revenue is not yet generated from products; progress depends on clinical evidence, regulatory approval, licensed intellectual property, financing, and external research, manufacturing, and drug-supply partners.
Develops telomere-targeting cancer treatments around ateganosine, an investigational small molecule also known in trials as THIO. The lead program is being tested in non-small cell lung cancer: THIO-101 sequences ateganosine with Regeneron's PD-1 inhibitor cemiplimab, while THIO-104 compares the regimen with investigator-choice chemotherapy in third-line disease. A preclinical second-generation telomere-targeting program complements the clinical work.
Runs a lean research operation from Chicago, using contract research and manufacturing organizations, remote U.S. staff, and development subsidiaries in Australia and Romania; its current clinical footprint is largely international. Core rights come from UTSW license agreements, and THIO-101 depends on Regeneron's no-cost drug supply and related NSCLC exclusivity. Has no approved products or product revenue, with future commercialization dependent on clinical evidence, regulatory approval, financing, and either internal capabilities or partners.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $27.6M · Total debt $0 · Total assets $28.2M · Shareholders' equity $20.7M
- Revenue
- $0
- Operating income
- −$8.3M
- Net income
- −$7.9M
No dividends on record.
| Institutions37 holders · as of Jun 30, 2026 | 22.24% | 13.52M shares | |
| Insiders1 holder · as of Sep 1, 2026 | 1.21% | 735.7K shares | |
| Otherremainder | 76.55% | 46.57M shares |
60.83M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Solas Capital Management, LLCInstitution | 4.98% | 3.03M | 13Fas of Jun 30, 2026 |
Alyeska Investment Group, L.P.Institution | 4.11% | 2.50M | 13Fas of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.97% | 2.41M | 13Fas of Jun 30, 2026 |
683 Capital Management, LLCInstitution | 1.75% | 1.07M | 13Fas of Jun 30, 2026 |
Centric Wealth ManagementInstitution | 1.31% | 796,723 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 28, 2026 | Ramiro Guerrero | director | +46,620 | $1.35 |
| Aug 27, 2026 | Ramiro Guerrero | director | +78,239 | $1.39 |
| Aug 26, 2026 | Ramiro Guerrero | director | +8,931 | $1.39 |
| Aug 24, 2026 | Ramiro Guerrero | director | +1,794 | $1.33 |
| Aug 20, 2026 | Ramiro Guerrero | director | +11,899 | $1.37 |
- Merck
Keytruda's PD-1 franchise sets the NSCLC immunotherapy benchmark.
- Regeneron
Libtayo is the partnered PD-1 backbone and an NSCLC rival.
- Bristol-Myers Squibb
Opdivo and Yervoy offer entrenched checkpoint regimens for NSCLC.
- Eli Lilly
Cyramza/docetaxel and Retevmo contest later-line NSCLC niches.
- AstraZeneca (ADR)
Imfinzi anchors a large PD-L1 franchise across NSCLC settings.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MAIA Biotechnology | $1.37 | −1.08% | $83.3M | — | — | — | — |
| Merck | $152.20 | +0.37% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Regeneron | $850.48 | −0.18% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Eli Lilly | $1,165.49 | +0.53% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| AstraZeneca (ADR) | $164.21 | +1.58% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Median | 24.3 | 15.2 | 5.6 | +6.4% |